ReNeuron Group PLC represents strong values and a corporate philosophy centered on innovation and excellence in the field of regenerative medicine. With an unwavering commitment to improving patients' lives, ReNeuron focuses on developing novel cell-based therapies to address critical medical needs. Their scientific expertise and state-of-the-art research facilities enable the company to advance groundbreaking treatments for conditions such as stroke and retinal diseases. ReNeuron Group PLC strives for ongoing collaboration with leading healthcare professionals and industry partners to deliver transformative therapies that have the potential to revolutionize the healthcare landscape.

ReNeuron Group PLC is primarily present in the United Kingdom.

ReNeuron Group PLC, a leading biotech company, has achieved several significant milestones. They have successfully developed and launched their innovative stem cell therapies, revolutionizing the field of regenerative medicine. The company has also conducted successful clinical trials, demonstrating the safety and efficacy of their treatments. ReNeuron has formed strategic partnerships with renowned academic institutions and pharmaceutical companies, further boosting their research and development capabilities. Additionally, they have received regulatory approvals for their therapies, paving the way for commercialization. ReNeuron Group PLC continues to make remarkable strides in unlocking the potential of stem cells for treating a range of debilitating diseases.

ReNeuron Group PLC is a leading biotechnology company specializing in the development of cell-based therapies. Founded in 1997, ReNeuron has built a solid reputation for its groundbreaking research in stem cell technologies. The company focuses on developing treatments for various debilitating diseases, including stroke, retinitis pigmentosa, and critical limb ischemia. With its innovative therapies and committed research efforts, ReNeuron aims to provide effective, long-term solutions for patients in need. Over the years, ReNeuron Group PLC has garnered recognition for its scientific advancements and remains dedicated to advancing the field of regenerative medicine.

The main competitors of ReNeuron Group PLC in the market include companies such as StemCells Inc., Athersys Inc., and Mesoblast Limited.

ReNeuron Group PLC is primarily active in the biotechnology and pharmaceutical industries.

The business model of ReNeuron Group PLC is focused on developing and commercializing cell-based therapies for the treatment of diseases and injuries. The company specializes in stem cell research and uses its unique proprietary technologies to create advanced therapies for conditions like stroke, retinal diseases, and peripheral arterial disease. ReNeuron Group PLC aims to capitalize on the potential of cell-based treatments and is dedicated to advancing the field of regenerative medicine. By leveraging their expertise in stem cell science, the company strives to provide innovative solutions that address significant unmet medical needs and improve patient outcomes.

ReNeuron Group KGV ir 0,19.

ReNeuron Group KUV ir 0,03.

AlleAktien kvalitātes vērtējums ReNeuron Group ir 4/10.

gaidāmā ReNeuron Group apgrozījums ir 660 540,00 GBP.

gaidāmā ReNeuron Group peļņa ir 103 935,06 GBP.

The ReNeuron Group PLC is a biopharmaceutical company that focuses on the development of cell therapies for serious diseases. The business model of ReNeuron Group includes three different divisions: therapeutics, research, and services.

ReNeuron Group izmaksā dividendes 0 GBP, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt ReNeuron Group vai uzņēmums nedod dividendes.

ReNeuron Group ISIN ir GB00BF5G6K95.

ReNeuron Group WKN ir A2JBKZ.

ReNeuron Group simbols ir RENE.L.

Pēdējo 12 mēnešu laikā ReNeuron Group maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos ReNeuron Group plāno maksāt dividendes 0 GBP apmērā.

ReNeuron Group pašreizējā dividendu rentabilitāte ir .

ReNeuron Group maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

ReNeuron Group pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 GBP. Tas atbilst dividendes ražībai 0 %.

ReNeuron Group tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu ReNeuron Group apmērā 0 GBP, kas tika izmaksāta 8.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 8.09.2024..

Pēdējās dividendes izmaksa notika 8.09.2024..

Gadā 2023, ReNeuron Group izmaksāja 0 GBP dividendes.

ReNeuron Group dividendes tiek izmaksātas GBP.